Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH

Name: Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH
Published: 2012
License: Public Domain

Gilead Sciences · 2012

ClinicalTrials.gov · Datasets · License: Public Domain · 2012

Open Source ↗

cirrhosis monoclonal-antibody

liver fibrosis due to nash, nash, cirrhosis, compensated liver disease, monoclonal antibody, loxl2, simtuzumab, nonalcoholic steatohepatitis, hepatic venous pressure gradient, hvpg, nafld, mre

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 870460
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.